Format

Send to

Choose Destination
Leukemia. 2019 May 14. doi: 10.1038/s41375-019-0475-z. [Epub ahead of print]

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Author information

1
Department of Internal Medicine III, Ulm University, 89081, Ulm, Germany. Stephan.Stilgenbauer@uniklinik-ulm.de.
2
Department of Hematology, Institute Paoli-Calmettes, Marseille, France.
3
Department I of Internal Medicine, Center for Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
4
Department of Hematology/Oncology, Goethe University Hospital, Frankfurt am Main, Germany.
5
Universitair Ziekenhuis Gent, Gent, Belgium.
6
Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
7
Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
8
Department of Hematology, Cliniques Universitaires Saint-Luc & Université Catholique de Louvain, B-1200, Brussels, Belgium.
9
IUCT-Oncopole, Toulouse, France.
10
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
11
Department of Medicine V, University Hospital Heidelberg, Department of Molecular Therapy in Haematology & Oncology, NCT/DKFZ, Heidelberg, Germany.
12
Department of Medical Oncology and Hematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
PMID:
31089249
DOI:
10.1038/s41375-019-0475-z

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center